Treatment of advanced thyroid cancer: role of molecularly targeted therapies

Lorinda L. Covell, Apar Kishor P Ganti

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.

Original languageEnglish (US)
Pages (from-to)311-324
Number of pages14
JournalTargeted Oncology
Volume10
Issue number3
DOIs
StatePublished - Sep 5 2015

Fingerprint

Thyroid Neoplasms
Therapeutics
Phosphotransferases
Clinical Trials
Drug Therapy

Keywords

  • Molecularly targeted therapies
  • Multi-kinase inhibitors
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Treatment of advanced thyroid cancer : role of molecularly targeted therapies. / Covell, Lorinda L.; Ganti, Apar Kishor P.

In: Targeted Oncology, Vol. 10, No. 3, 05.09.2015, p. 311-324.

Research output: Contribution to journalReview article

@article{ef89897e8c4c472bafcab45af41d36b6,
title = "Treatment of advanced thyroid cancer: role of molecularly targeted therapies",
abstract = "Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.",
keywords = "Molecularly targeted therapies, Multi-kinase inhibitors, Thyroid cancer",
author = "Covell, {Lorinda L.} and Ganti, {Apar Kishor P}",
year = "2015",
month = "9",
day = "5",
doi = "10.1007/s11523-014-0331-z",
language = "English (US)",
volume = "10",
pages = "311--324",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - Treatment of advanced thyroid cancer

T2 - role of molecularly targeted therapies

AU - Covell, Lorinda L.

AU - Ganti, Apar Kishor P

PY - 2015/9/5

Y1 - 2015/9/5

N2 - Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.

AB - Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.

KW - Molecularly targeted therapies

KW - Multi-kinase inhibitors

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=84940894311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940894311&partnerID=8YFLogxK

U2 - 10.1007/s11523-014-0331-z

DO - 10.1007/s11523-014-0331-z

M3 - Review article

C2 - 26335853

AN - SCOPUS:84940894311

VL - 10

SP - 311

EP - 324

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -